Silversmith Partners I GP, LLC — 13F Portfolio

Silversmith Partners I GP, LLC (CIK 0001866164) is a general partner vehicle affiliated with Silversmith Capital Partners, a Boston, MA–based growth equity firm focused on software, technology-enabled services, and healthcare services. The GP oversees the first-generation Silversmith fund structure and exercises investment discretion over portfolio company holdings that become publicly listed, triggering 13F filing obligations once the reporting threshold is met. The broader Silversmith platform, founded by Jeffrey Crisan, Todd MacLean, and James Quagliaroli, is organized as a specialist private equity / growth equity manager. It concentrates on founder-led, capital-efficient companies, typically holding significant minority stakes and seeking to support long-duration organic growth. Silversmith Partners I GP, LLC appears in the public record primarily via its SEC Form 13F filings, which capture U.S.-listed equity positions held on behalf of its private funds and co-investment vehicles. For allocators, the GP’s 13F History provides a narrow but useful window into the public equity sleeve of a largely private portfolio—typically representing post-IPO or post–liquidity event holdings rather than a standalone public markets trading strategy. These snapshots can be organized into a reconstructed 13F Portfolio Composition and subjected to a normalized Historical Track Record using a Portfolio Simulator or Backtesting Service, while recognizing that the underlying mandate remains fundamentally private equity–driven.

Silversmith’s investment strategy is grounded in sector-focused growth equity. The firm targets B2B software/SaaS, information services, and technology-enabled or healthcare services businesses that are often founder-controlled, growing rapidly, and frequently already profitable. The emphasis is on durable, recurring-revenue models, high customer retention, and strong unit economics, with value creation driven by compounding revenue growth rather than financial engineering. Within this framework, Silversmith Partners I GP, LLC represents the governance and decision-making nexus for a specific vintage of the Silversmith funds. The GP typically leads or co-leads investments, taking significant board roles and partnering with management on go-to-market, product, and organizational scaling. Holding periods are multi-year, with exits commonly realized via strategic sale, recapitalization, or IPO. When a portfolio company lists publicly, the resulting equity stakes—often subject to lock-ups and staged sell-downs—become visible in the 13F context. The 13F filings for Silversmith Partners I GP, LLC therefore tend to show a small number of concentrated positions, predominantly in software and technology-enabled or healthcare service issuers. Trading activity is usually event-driven rather than tactical: position entries typically correspond to IPOs or direct listings of existing portfolio companies, and reductions correspond to secondary offerings or open-market disposals executed over time. As a result, the observed capital trajectory in any 13F-based replication is more reflective of exit timing and liquidity management from private holdings than of traditional public equity security selection. When analyzed through Performance Backtests Online, the GP’s filings can be used to construct a time series that approximates the public-equity component of Silversmith’s strategy. However, allocators should interpret any simulated compounding behavior or Sharpe Ratio estimates as characteristics of the realized liquidity path of private deals, rather than as evidence of an independent public markets process.

Silversmith Partners I GP, LLC is best understood as a GP-level entity within a Boston-based, sector-specialist growth equity platform, rather than as a conventional long-only or hedge fund manager. Its 13F reports under CIK 0001866164 capture a narrow slice of the overall strategy: public equity stakes that arise when private portfolio companies access the public markets. These filings typically show low-turnover, concentrated exposures in software, technology-enabled services, and healthcare-related issuers, consistent with Silversmith’s sector mandate. For allocators seeking to contextualize the GP’s public holdings, a reconstructed 13F Portfolio Composition across time can be used to examine sector tilts, issuer concentration, and the evolution of positions during post-IPO sell-downs. A normalized Historical Track Record built from 13F-based historical replication can illustrate the capital trajectory that such holdings would have generated if held on a mark-to-market basis, while risk measures like Max Drawdown Depth and 13F-derived Sharpe Ratio estimates help frame risk-adjusted outcomes. These analytics, delivered via a Portfolio Simulator or Performance Backtests Online, should be interpreted as a complementary layer to traditional private equity due diligence rather than a substitute for it. The key analytical question for an allocator is how sensitive this pattern of concentrated, growth-oriented, post-IPO holdings would be to shifts in market regimes—for example, a prolonged environment of higher interest rates, value-style leadership, or reduced IPO activity—and how that, in turn, would interact with the underlying private equity value-creation model that is not directly observable in 13F data.

The risk profile associated with Silversmith Partners I GP, LLC’s 13F-reportable positions is shaped by three main features: sector concentration, growth orientation, and name concentration. The software/SaaS and healthcare services focus exposes the public sleeve to factors such as high-growth, quality, and momentum styles, along with sensitivity to interest rate expectations and risk appetite for long-duration cash flows. These exposures can produce above-market volatility, especially during periods of multiple compression in growth equities. Name concentration is another defining characteristic. Because the 13F portfolio typically originates from a limited number of successful private investments reaching the public markets, the top holdings often represent a large share of disclosed market value. This concentration amplifies idiosyncratic risk linked to company-specific execution, competitive dynamics, and post-IPO trading behavior. Quarter-to-quarter changes in reported positions can be lumpy, reflecting stepwise sell-downs, secondary offerings, or full exits, leading to punctuated shifts in the 13F footprint rather than smooth turnover. From a risk analytics standpoint, allocators can examine reconstructed volatility, drawdown sequences, and downside behavior for the public holdings sleeve using a Portfolio Simulator or similar Backtesting Service. Metrics such as Max Drawdown Depth and a 13F-based Sharpe Ratio provide a lens on how the equity exposures derived from private deals would have behaved historically if held as reported, normalized to a user-defined notional. It is important to recognize that this lens omits the substantial portion of risk and value creation that occurs during the private ownership phase, where leverage, capital structure decisions, and operational initiatives are not visible in 13F data.